Skip to content
2000
Volume 20, Issue 3
  • ISSN: 1574-8863
  • E-ISSN: 2212-3911

Abstract

Background

Imipenem-cilastatin, a carbapenem antibiotic, is commonly used for severe bacterial infections. While generally well-tolerated, it can rarely cause central nervous system toxicity, including seizures. We have, herein, reported a case of imipenem-cilastatin-induced seizure in a 20-year-old patient.

Case Presentation

A 20-year-old male was admitted to the intensive care unit for febrile status epilepticus and acute respiratory distress syndrome. Initial evaluations ruled out underlying causes and anti-epileptic treatment has been initiated. Despite having an effective anti-epileptic treatment for three months of hospitalization, seizure recurrence occurred, leading to antibiotic regimen adjustment as the imputability of imipenem-cilastatin was suspected. After discontinuation of the involved drug, the patient remained neurologically stable. Previous literature has reported cases of imipenem-cilastatin-induced seizures, particularly in elderly patients or at higher dosages. The causality assessment was conducted using the updated French method, which rated the chronological criterion as C2 and the semiological criterion as S2. The intrinsic imputability score was I3, indicating plausible causality, and the extrinsic bibliographic score was B3.

Conclusion

Our case has highlighted the importance of promptly recognizing imipenem-cilastatin-induced epileptic seizures in order to treat them more effectively and thus optimize the patient’s care. Therefore, we emphasize that clinicians be vigilant about the side effects of its use, particularly in patients with neurological susceptibilities. We also advocate a personalized choice of antibiotics, taking into account both antimicrobial efficacy and potential adverse effects, for better outcomes with fewer risks.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cds/10.2174/0115748863324094240919114700
2024-10-07
2025-10-10

  • From This Site

    /content/journals/cds/10.2174/0115748863324094240919114700
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. CannonJ.P. LeeT.A. ClarkN.M. SetlakP. GrimS.A. The risk of seizures among the carbapenems: A meta-analysis.J. Antimicrob. Chemother.20146982043205510.1093/jac/dku11124744302
     [Google Scholar]
  2. SinghD. Amikacin/imipenem/cilastatin.Reactions Weekly202118371434310.1007/s40278‑021‑88642‑2
     [Google Scholar]
  3. BasilJ.H. Imipenem/meropenem overdose.Reactions Weekly201314641252510.1007/s40278‑013‑5058‑6
     [Google Scholar]
  4. NiellyH. Imipenem/cilastatin.Reactions Weekly201314381181810.1007/s40278‑013‑1274‑3
     [Google Scholar]
  5. ZhaoF-G. Imipenem/cilastatin: Epileptic seizure in an elderly patient: Case report.Reactions Weekly.201214212829
     [Google Scholar]
  6. HoffmanJ. TrimbleJ. BrophyG.M. Safety of imipenem/cilastatin in neurocritical care patients.Neurocrit. Care200910340340710.1007/s12028‑008‑9170‑z19116700
     [Google Scholar]
  7. ChenW. ZhangD. LianW. WangX. DuW. ZhangZ. GuoD. ZhangX. ZhanQ. LiP. Imipenem population pharmacokinetics: Therapeutic drug monitoring data collected in critically Ill patients with or without extracorporeal membrane oxygenation.Antimicrob. Agents Chemother.2020646e00385-2010.1128/AAC.00385‑2032253220
     [Google Scholar]
  8. a CalandraG.B. BrownK.R. GradL.C. AhonkhaiV.I. WangC. AzizM.A. Review of adverse experiences and tolerability in the first 2,516 patients treated with imipenem/cilastatin.Am. J. Med.1985786737810.1016/0002‑9343(85)90104‑43859218
     [Google Scholar]
  9. b WongV.K. WrightH.T.Jr RossL.A. MasonW.H. InderliedC.B. KimK.S. Imipenem/cilastatin treatment of bacterial meningitis in children.Pediatr. Infect. Dis. J.199110212212510.1097/00006454‑199102000‑000092062603
     [Google Scholar]
  10. MillerA.D. BallA.M. BookstaverP.B. DornblaserE.K. BennettC.L. Epileptogenic potential of carbapenem agents: Mechanism of action, seizure rates, and clinical considerations.Pharmacotherapy201131440842310.1592/phco.31.4.40821449629
     [Google Scholar]
  11. GoetzT. ArslanA. WisdenW. WulffP. GABAA receptors: Structure and function in the basal ganglia.Prog. Brain Res.2007160214110.1016/S0079‑6123(06)60003‑417499107
     [Google Scholar]
  12. MihicS.J. HarrisR.A. GABA and the GABAA receptor.Alcohol Health Res. World199721212713115704348
     [Google Scholar]
  13. WanleenuwatP. SuntharampillaiN. IwanowskiP. Antibiotic-induced epileptic seizures: Mechanisms of action and clinical considerations.Seizure20208116717410.1016/j.seizure.2020.08.01232827980
     [Google Scholar]
  14. WilliamsP.D. BennettD.B. ComereskiC.R. Animal model for evaluating the convulsive liability of beta-lactam antibiotics.Antimicrob. Agents Chemother.198832575876010.1128/AAC.32.5.7583395104
     [Google Scholar]
  15. Ragnar NorrbyS. Carbapenems in serious infections: A risk-benefit assessment.Drug Saf.200022319119410.2165/00002018‑200022030‑0000310738843
     [Google Scholar]
/content/journals/cds/10.2174/0115748863324094240919114700
Loading

  • Article Type:     Case Report
Keyword(s): case report; drug monitoring; Imipenem-cilastatin; pharmacovigilance; seizure; side effects

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test